Rosati A, Boncristiano A, Doccini V, et al. – Via conducting a single center, prospective, observational study, researchers evaluated the long-term effectiveness and tolerability of stiripentol (STP) as an adjunctive therapy for different types of refractory epilepsy. They reviewed the records of all people consecutively treated with STP as add-on therapy for refractory epilepsies, irrespective of their being focal, generalized, or both, and followed at Meyer Children's Hospital between January 2007 and May 2018. The drug scheme administration consisted of a beginning dose of STP of 10-15 mg/kg/d with increases each week, up to a maximum of 50 mg/kg/d, based on both age and weight. In total, 132 people aged from 5 months to 43 years received add-on STP, including 30 individuals with Dravet syndrome. The most commonly used add-on drugs were benzodiazepines, mainly clobazam. The long-term effectiveness of add-on STP treatment in patients with different forms of refractory epilepsy, including focal onset epilepsy without bilateral tonic-clonic seizures, was confirmed in this analysis. To confirm the effectiveness of STP in focal epilepsy, further confirmations based on prospectively designed studies are needed.